# Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

> **NCT04849364** · PHASE2 · TERMINATED · sponsor: **Bryan Schneider, MD** · enrollment: 52 (actual)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Talazoparib
- **DRUG:** Pembrolizumab
- **DRUG:** Inavolisib

## Key facts

- **NCT ID:** NCT04849364
- **Lead sponsor:** Bryan Schneider, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-24
- **Primary completion:** 2024-10-24
- **Final completion:** 2024-12-02
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Funder Decision
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04849364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04849364, "Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04849364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*